Contrasting clinical characteristics and treatment patterns in women with newly diagnosed advanced-stage epithelial ovarian cancer in Australia, South Korea and Taiwan

Hung-Hsueh Chou; Sian Fereday; Anna DeFazio; Chih-Long Chang; David Bowtell; Heng-Cheng Hsu; Nadia Traficante; Soo Young Jeong; Wen-Fang Cheng; Dinuka Ariyarantne; Australian Ovarian Cancer Study Group; Teresa Tung; Viraj Rajadhyaksha; Won-Hee Lee; David Brown; Byoung-Gie Kim

doi:10.3802/jgo.2023.34.e3

Contrasting clinical characteristics and treatment patterns in women with newly diagnosed advanced-stage epithelial ovarian cancer in Australia, South Korea and Taiwan

J Gynecol Oncol. 2023 Jan;34(1):e3. doi: 10.3802/jgo.2023.34.e3. Epub 2022 Oct 5.

Authors

Hung-Hsueh Chou^#^{1

2}, Sian Fereday^#^{3

4}, Anna DeFazio^{5

6

7}, Chih-Long Chang⁸, David Bowtell^{3

4}, Heng-Cheng Hsu⁹, Nadia Traficante^{3

4}, Soo Young Jeong¹⁰, Wen-Fang Cheng¹¹, Dinuka Ariyarantne³; Australian Ovarian Cancer Study Group³; Teresa Tung¹², Viraj Rajadhyaksha¹³, Won-Hee Lee¹⁴, David Brown¹⁵, Byoung-Gie Kim¹⁶

Affiliations

¹ Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan.
² School of Medicine, National Tsing Hua University, Hsinchu, Taiwan.
³ Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
⁴ Sir Peter MacCallum Cancer Centre, Department of Oncology, The University of Melbourne, Parkville, Vic, Australia.
⁵ Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, NSW, Australia.
⁶ The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, NSW, Australia.
⁷ Department of Gynaecological Oncology, Westmead Hospital, Sydney, NSW, Australia.
⁸ Department of Obstetrics and Gynecology, MacKay Memorial Hospital & Department of Medicine, MacKay Medical College, Taipei, Taiwan.
⁹ Department of Obstetrics and Gynecology, National Taiwan University Hospital Hsin-Chu Branch, Hsin-Chu City, Taiwan.
¹⁰ Department of Obstetrics and Gynecology, Kangnam Sacred Heart Hospital, The Hallym University School of Medicine, Seoul, Korea.
¹¹ Department of Obstetrics and Gynecology, National Taiwan University Hospital, Taipei, Taiwan.
¹² Medical Affairs, AstraZeneca International, Baar, Switzerland.
¹³ Medical Affairs, AstraZeneca United Kingdom, Cambridge, United Kingdom.
¹⁴ Medical Affairs, AstraZeneca South Korea, Seoul, Korea.
¹⁵ Medical Affairs, AstraZeneca Australia, Macquarie Park, NSW, Australia.
¹⁶ Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. bgkim@skku.edu.

^# Contributed equally.

Abstract

Objective: The real-world INFORM study analyzed sociodemographics, treatment patterns and clinical outcomes for patients with newly diagnosed advanced epithelial ovarian cancer (EOC) in Australia, South Korea (S.Korea) and Taiwan preceding incorporation of poly(ADP-ribose) polymerase inhibitors into clinical practice.

Methods: Retrospective data from patients diagnosed with EOC (high-grade serous EOC for Taiwan) between January 2014 and December 2018 with ≥12 months follow-up from diagnosis were analyzed descriptively. Survival was evaluated by Kaplan-Meier with two-sided 95% confidence interval (CI).

Results: Of the 987 patients (Australia, 223; S.Korea, 513; Taiwan, 251), 98% received platinum-based chemotherapy (CT). In S.Korea and Taiwan 76.0% and 78.9% respectively underwent primary cytoreductive surgery; in Australia, 56.5% had interval debulking surgery. Bevacizumab was included in primary/maintenance therapy for 22.4%, 14.6% and 6.8% of patients in Australia, S.Korea and Taiwan, respectively. Patients receiving bevacizumab were high-risk (reimbursement policy) and achieved similar real-world progression-free survival (PFS) compared with CT only. Overall, the median real-world PFS (months; 95% CI) was similar across Australia (16.0 [14.63-18.08]), S.Korea (17.7 [16.18-19.27]) and Taiwan (19.1 [17.56-22.29]).

Conclusion: This study reveals poor prognosis despite differences in demographics and treatment patterns for patients with EOC across Asia-Pacific suggesting the need for biomarker-driven novel therapies to improve outcomes.

Keywords: Adjuvant Chemotherapy; Bevacizumab; Maintenance Therapy; Neoadjuvant Chemotherapy; Ovarian Cancer; Surgery.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Bevacizumab / therapeutic use
Carcinoma, Ovarian Epithelial / drug therapy
Cytoreduction Surgical Procedures
Female
Humans
Neoadjuvant Therapy
Ovarian Neoplasms* / drug therapy
Ovarian Neoplasms* / therapy
Poly(ADP-ribose) Polymerase Inhibitors / therapeutic use
Republic of Korea / epidemiology
Retrospective Studies
Taiwan / epidemiology

Substances

Bevacizumab
Poly(ADP-ribose) Polymerase Inhibitors